TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of Participants With Clinically Significant Changes in Laboratory Evaluation, Vital Signs, Electrocardiogram (ECG) and Physical Examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Decay Half-Life (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of Cognitive Decline by Means of a Computerized Battery of Neuropsychologic Tests
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Muscle Fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Patient-oriented composite outcome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Treatment response (50% decrease in HAM-D24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission (HAM-D24 score below 8)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait speed during dual task conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics parameters (tlag, Cmax, tmax, AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of exclusive and total breastfeeding
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Respiratory stimulation effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Facial gingival level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Dabigatran: Area Under the Curve 0 to Infinity (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Dabigatran: Maximum Measured Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving ABC goals
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cravings at one month following opioid tapering
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of fetal umbilical artery pH below 7.20
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 6 minute walk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of Platelet Aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction in urine leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants Who Had a Mood Relapse
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Non-relapsed Deaths by 100 Days Post-transplant
Endpoint domain: Mortality/survival
Primary endpoint: Event-free Survival at 6 Months
Endpoint domain: Mortality/survival
Primary endpoint: Number of Non-relapsed Deaths by 6 Months Post-transplant
Endpoint domain: Mortality/survival
Primary endpoint: Changes in RV ICD lead function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: soft tissue width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline vitamin D status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: treatment related mortality and morbidity
Endpoint domain: Mortality/survival
Primary endpoint: Knowledge about covid-19
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average total ASQ-3 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: scale of Schirmer I test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: scale of corneal fluorescein staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: scale of noninvasive tear breakup time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of phlebitis
Endpoint domain: Adverse events/effects
Primary endpoint: Raw Score of Alberta Infant Motor Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development Quotient of PDMS-II
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum kallistatin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Yale-Brown Obsessive-Compulsive Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline EuroQoL-5 dimension (EQ-5D) value
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline Visual Analog Pain Scale (VAS) of back pain
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Number of Participants With Vital Signs Changes of Potential Clinical Importance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Electrocardiogram (ECG) Values Outside Range of Potential Clinical Importance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Cognitive flexibility
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Mental Effort
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Perceived exertion
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in Brain oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Supportive Care Needs
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: rate of HBeAg seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Primary Immunogenicity Endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: histologic response to preoperative chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in visual analogue scale (VAS) for anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pulmonary capillary blood volume (Vc)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: heart-rate corrected QT (QTc) interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average Stool Output Difference (First Week v. Second Week) for Patients With Ostomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Average Stool Output Difference (First Week v. Second Week) for Patients in Intestinal Continuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Area Under Curve (AUC) 0-inf Ambisome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in systolic and diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Subjects With Influenza-like Clinical Illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laboratory Confirmed Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Relative bioavailability of ARQ 197
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-month graft survival
Endpoint domain: Mortality/survival
Primary endpoint: Eyelid closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: 24-hour ambulatory systolic blood pressure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: FFR (Fractional Flow Reserve) at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Presence of arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Presence of stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of any grade 3 or higher non-hematological or grade 4 or higher hematological toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of pathological complete remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: anatomic success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve over a dose-interval of plasma CORT125134 (AUCtau)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration of plasma CORT125134 (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC from the time of dosing until 24 hours later of plasma CORT125134 (AUC0-24h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With 18F-DCFPyL PET/CT Detected Sites of Metastatic Renal Cell Carcinoma (RCC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With a Correlation Between Radiotracer Uptake on 18F-DCFPyL PET/CT and Conventional Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores on a Scale for Telephone-administered ALSFRS-R
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Experiencing an Adverse Event During the Treatment Period
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Experiencing an Adverse Event by the End of the Trial in the OLE Period
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline in Tetrahydrocannabinol (Delta-9-THC-COOH) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Past 30-Day Cannabis Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Withdrawal Severity as measured by Clinical Opiate Withdrawal Scale (COWS) peak score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic quality of MRA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of awkward postures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FV intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychosocial Adjustment/ Everyday Functioning
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Safety and toleration of the heat washout device
Endpoint domain: Adverse events/effects
Primary endpoint: Differences in vaginal blood flow following visual sexual stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Generation of B-cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Alveolar crest-Interdental contact point (AC-IC mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Papilla Height Loss (PHL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Papilla presence index (PPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change on the Scale for the Assessment and Rating of Ataxia (SARA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Preference for chaperone during examination
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: BOLD fMRI activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Study Intervention-Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Total Number of Days With Pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Best Overall Response Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of subjects completing remote assessments
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Improvement Index on Cogmed™
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Performances on near transfer working memory tasks
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Blood-Oxygenation Level-Dependent Functional MRI Measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in T2 Relaxation Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sit-to-stand independently (percent)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with clinical outcome at discharge
Endpoint domain: Mortality/survival
Primary endpoint: Varicella seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: MMR titres
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pharmacokinetics of oral midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reaction time of flip switch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Direction of flip switch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Definitive surgery choice
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Completeness and Quality of PTSD Interview
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: GPS' confidence on the conclusion
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Endothelial (dys)function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Platelet count change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Respiratory distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Migration of leads
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Changes in the inhalation technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Plasma Low Density Lipoprotein-cholesterol (LDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: No AF Recurrences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants with postoperative morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline weight assessed at different time points to determine maximal weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in weight assessed at different time points to determine weight regain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morphine consumption (mg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scar Appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Long-term Clinical Success Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Serum Uric Acid (sUA) < 6 mg/dL Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Caries Arrest of Teeth in the SDF Group Measured by Change in Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caries Arrest of Teeth in the SDF Group Measured by Dentin Color
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Signs of Pulpal Pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: accuracy and precision of the TAT compared to the PAT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of ABT-888 and gemcitabine hydrochloride
Endpoint domain: Adverse events/effects
Endpoint subdomain: Any subdomain
Primary endpoint: Intelligence quotient
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Determination of tolerability and maximum tolerated dose (MTD)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with AEs qualified as dose-limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of conversion to complete response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in renal resistivity index (RRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Renal Venous Stasis Index (RSVI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Central retinal layer thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of fluid in the retina
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuromonitoring modifications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Non-serious Adverse Events (AEs) and Serious AEs (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Overall Response Rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: ABI measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: improved outcomes in substance use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improved psychological functioning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Subjects With Solicited Local Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Solicited General Symptoms (Dose 1)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in pain on load NRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful medical abortion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of vaccinees infected with HPIV3-EbovZ GP vaccine virus
Endpoint domain: Adverse events/effects
Primary endpoint: Number of days vaccine virus was shed
Endpoint domain: Adverse events/effects
Primary endpoint: Conversion to Alzheimer's disease
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of Respiratory virus infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants Safely Tolerating Sabril
Endpoint domain: Adverse events/effects
Primary endpoint: Time to Reach the Maximum Plasma Concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: structural integrity of repaired rotator cuff tendon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Intra-Ocular Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal tolerated dose (MTD)
Endpoint domain: Adverse events/effects
Primary endpoint: dose limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of intubation
Endpoint domain: Adverse events/effects
Primary endpoint: Restoration of Central Venous Catheter (CVC) Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of device and procedure related serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Acute Procedural Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Chronic Feasibility: Proportion of patients with documented electrical isolation of the pulmonary veins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of at least one complication requiring a surgical re-intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Persistence of an important / major trouble of the scar measured by a scar-trouble scale filled in by the patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Auto-evaluation of patient's scar esthetical result with a visual analog scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: repair integrity analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electrophysiological evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mean global severity index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Maturation of cognition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percent of Identified Eligibles Who Enroll
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of Participants Completing the 3RP-AYA Program
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Serotype-specific Geometric Mean Concentration of IgG Antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number and Percentage of Subjects With Serotype-specific IgG Antibody Responses ≥ 0.35 μg/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number and Percentage of All AEs Including SAEs Occurring in Greater Than 1% Subjects by Severity and Relatedness
Endpoint domain: Adverse events/effects